These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21343372)

  • 41. Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
    Pagel CN; Kularathna PK; Sanaei R; Young ND; Hooper JD; Mackie EJ
    Prostate; 2022 May; 82(6):723-739. PubMed ID: 35167724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation.
    Liu Y; Berendsen AD; Jia S; Lotinun S; Baron R; Ferrara N; Olsen BR
    J Clin Invest; 2012 Sep; 122(9):3101-13. PubMed ID: 22886301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
    Zhao X; Zhu DM; Gan WJ; Li Z; Zhang JL; Zhao H; Zhou J; Li DC
    Oncol Rep; 2013 Mar; 29(3):1019-26. PubMed ID: 23254994
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.
    Tseng FJ; Chen YC; Lin YL; Tsai NM; Lee RP; Chung YS; Chen CH; Liu YK; Huang YS; Hwang CH; Lai YK; Liao KW
    Cancer Biol Ther; 2010 Nov; 10(9):865-73. PubMed ID: 20818186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment.
    Lee YC; Gajdosik MS; Josic D; Clifton JG; Logothetis C; Yu-Lee LY; Gallick GE; Maity SN; Lin SH
    Mol Cell Proteomics; 2015 Mar; 14(3):471-83. PubMed ID: 25527621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis.
    Choi HS; Lee K; Kim MK; Lee KM; Shin YC; Cho SG; Ko SG
    Oncotarget; 2016 Apr; 7(16):21775-85. PubMed ID: 26967562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.
    Yamaguchi M; Zhu S; Zhang S; Wu D; Moore TM; Snyder JP; Shoji M
    Cell Tissue Res; 2014 Jul; 357(1):245-52. PubMed ID: 24723227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
    Elshafae SM; Dirksen WP; Alasonyalilar-Demirer A; Breitbach J; Yuan S; Kantake N; Supsavhad W; Hassan BB; Attia Z; Alstadt LB; Rosol TJ
    Prostate; 2020 Jun; 80(9):698-714. PubMed ID: 32348616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line.
    Shimamura T; Amizuka N; Li M; Freitas PH; White JH; Henderson JE; Shingaki S; Nakajima T; Ozawa H
    Biomed Res; 2005 Aug; 26(4):159-72. PubMed ID: 16152732
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Caprylic acid (C8:0) promotes bone metastasis of prostate cancer by dysregulated adipo-osteogenic balance in bone marrow.
    Wang C; Wang J; Chen K; Pang H; Li X; Zhu J; Ma Y; Qiu T; Li W; Xie J; Zhang J
    Cancer Sci; 2020 Oct; 111(10):3600-3612. PubMed ID: 32770813
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Pang X; Yi Z; Zhang X; Sung B; Qu W; Lian X; Aggarwal BB; Liu M
    Cancer Res; 2009 Jul; 69(14):5893-900. PubMed ID: 19567671
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
    Haider MT; Holen I; Dear TN; Hunter K; Brown HK
    Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.
    Akatsu Y; Yoshimatsu Y; Tomizawa T; Takahashi K; Katsura A; Miyazono K; Watabe T
    Cancer Sci; 2017 Jan; 108(1):151-155. PubMed ID: 28133920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of vascular endothelial growth factor on osteoblasts and osteoclasts.
    Huang H; Ma L; Kyrkanides S
    Am J Orthod Dentofacial Orthop; 2016 Mar; 149(3):366-73. PubMed ID: 26926024
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model.
    Ackerman R; Backer JM; Backer M; Skariah S; Hamby CV
    Toxins (Basel); 2010 Sep; 2(9):2242-57. PubMed ID: 22069683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of PGK1 by prostate cancer cells induces bone formation.
    Jung Y; Shiozawa Y; Wang J; Wang J; Wang Z; Pedersen EA; Lee CH; Hall CL; Hogg PJ; Krebsbach PH; Keller ET; Taichman RS
    Mol Cancer Res; 2009 Oct; 7(10):1595-604. PubMed ID: 19825988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
    Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.